Mariona Graupera

All publications from my La make me happy, but this one is special because it stays in the family , you know what I mean ❤️!

Thank you to the Leducq Fondation for supporting our work

Many thanks to all collaborators but specially to Marc Claret and Katrien de Bock for making it possible

Very happy to share our new publication on the role of mitochondrial dynamics in endothelial cells and its implications for whole-body metabolism.

kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...

Thank you for inviting me, and for hosting me that well. If you are a vascular biologist, and you are thinking to come next year to IVBM in Adelaide, do not think it twice, this is a vibrant society ❤️!

🥳🥳 We have more than 100 abstracts submitted for #GRC_Angiogenesis!!! Application deadline is TOMORROW!! don't miss it!

VAC_53_2025 - POSTDOCTORAL RESEARCH - Institut de Recerca contra la Leucèmia Josep Carreras Join the Josep Carreras Leukaemia Research Institute and contribute to our mission of innovating and advancing the fight against leukaemia and other hematologic diseases.

We have an open postdoc position to work on PTEN and vascular Malformations. If you are intersted, apply: careers.carrerasresearch.org/jobs/6107690...

Finally, thank you PTEN Research Foundation, for supporting our work

GrauperaLab
@MarionaGraupera
·
2min
This is a team effort with many involved, but I would especially thank @sandradcastillo.bsky.social the driving force of this work, and Eulàlia Baselga the clinician managing these patients

If you are interested in vascular malformations you may want to check our new work published today in Cancer Discovery, where we discover a somatic genetic event causing vascular malformations in PTEN hamartoma tumor syndrome (PHTS) aacrjournals.org/cancerdiscov...

I rising star! I could not be prouder ❤️!

EVBO is offering personalised #training for #EVBOmembers for ERC Starting Grant interview.
We want EVBO research to be funded by the ERC!
If interested, contact Prof. Taija Makinen @ taija.makinen@igp.uu.se by the 25th April.
More info: buff.ly/dexAhf7

By demonstrating that the differentiation state and the fate of endothelial cells dictate the cellular response to PIK3CA mutations, we provide a novel paradigm for understanding the mechanisms dictating tissue-specific overgrowth in PIK3CA-related congenital disorders

Our findings expose the (i) generation of large clones in veins and capillaries causing vascular malformations, (ii) silent presence in arterial cells without pathological manifestations; and (iii) rewire of cell fate in arterial precursors

Context-dependent response of endothelial cells to PIK3CA mutation Cancer mutations in the PIK3CA gene cause congenital disorders. The endothelium is among the most frequently affected tissues in these disorders, displaying aberrant vascular overgrowth in the form of...

We are excited to share our work on Context-dependent response of endothelial cells to PIK3CA mutation. A tour the force of many; thank you all for your invaluable contribution. @aangulou.bsky.social @ruibenedito.bsky.social @debocklab.bsky.social @sandradcastillo.bsky.social
bit.ly/4blKSqa

PIPgenerating ART: Where Art meet Science YouTube video by PIPgen

The freshly cooked video summarizing the Art project developed in the frame of our PIPgen MSCA DN: “PIPgenerating ART: Where Art meet Science “. A collaborative activitys between our students and the Cambridge School of Visual Performing Arts.
www.youtube.com/watch?v=tQxA...

Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical tria...

Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪

Pls share 🌟Join the IMP as a Group Leader
We are 👀 for a colleague, ready to lead a groundbreaking research program. Enjoy generous funding, outstanding facilities & a vibrant scientific community in one of the world's most livable cities @impvienna.bsky.social
👉https://tinyurl.com/impgl2025

Beautiful as always ❤️